8-K: NovaBay Pharmaceuticals to Sell Avenova Assets for $9.5 Million, Plans Liquidation

NovaBay Pharmaceuticals has agreed to sell its Avenova brand assets to PRN Physician Recommended Nutriceuticals for $9.5 million in cash and intends to liquidate the company following the sale.

Summary

• NovaBay Pharmaceuticals has entered into an agreement to sell its Avenova eyecare product line to PRN Physician Recommended Nutriceuticals for $9.5 million in cash.
• The deal includes the sale of substantially all of NovaBay's operating assets related to Avenova, but excludes other product lines such as wound care, urology, and dermatology.
• The purchase price is subject to a net working capital adjustment, with a target working capital value of $800,000.
• An additional $500,000 will be held in escrow for up to six months to cover post-closing working capital adjustments and indemnification claims.
• Following the sale, NovaBay plans to pursue an orderly wind down and dissolution of the company, subject to stockholder approval.
• The company intends to distribute the net proceeds from the asset sale to its stockholders after paying off creditors and liabilities.
• The liquidation process is expected to take a minimum of nine months, as required by Delaware law.
• The transaction is expected to close in the fourth quarter of 2024, pending stockholder approval and other customary closing conditions.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is selling its main asset and liquidating, the deal is presented as a positive outcome for stockholders, with a clear plan for distribution of assets. The sale to a company that is expected to grow the brand is also a positive.

Positives

• The sale of Avenova assets allows stockholders to realize value from the brand.
• PRN is a well-established eyecare company, which may help Avenova grow.
• The company will distribute net proceeds to stockholders after paying off liabilities.
• The board of directors believes the asset sale is in the best interests of the company and its stockholders.

Negatives

• NovaBay will cease to operate as a going concern after the sale and liquidation.
• The liquidation process will take a minimum of nine months, delaying distributions to stockholders.
• There is a risk that the sale may not close if closing conditions are not met.
• The company will no longer have revenue generating assets after the sale.

Risks

• The asset sale is subject to stockholder approval and customary closing conditions, which may not be met.
• The liquidation process may be delayed or not completed as planned.
• The company may not be able to fully satisfy all liabilities and obligations.
• The amount of proceeds available for distribution to stockholders is uncertain and may be less than expected.
• There is a risk of potential litigation or regulatory issues that could impact the transaction or liquidation.

Future Outlook

NovaBay plans to liquidate and dissolve the company after the sale of the Avenova business, distributing remaining assets to stockholders after satisfying liabilities. The company expects the Avenova brand to continue to grow under PRN's leadership.

Management Comments

• Justin Hall, NovaBay CEO, stated that the transaction allows stockholders to realize the value created with the Avenova brand.
• Justin Hall believes they have found an ideal home for Avenova with PRN.
• Management expects the Avenova brand to continue to grow and flourish under PRN's leadership.

Industry Context

This announcement reflects a strategic shift for NovaBay, moving away from its eyecare business to focus on other areas or to wind down operations. The sale to PRN, a company with a strong presence in the eyecare market, suggests a consolidation trend in the industry.

Comparison to Industry Standards

• The sale of a specific product line for a set price is a common transaction in the pharmaceutical and healthcare industry.
• The inclusion of a working capital adjustment and an escrow account is standard practice in asset purchase agreements.
• The decision to liquidate the company after the sale is less common and suggests a strategic shift or a lack of viable alternatives for the remaining assets.
• Comparable companies that have sold assets include Alcon selling its surgical business to Bausch + Lomb, and Allergan selling its generics business to Teva. However, these transactions did not include a subsequent liquidation of the parent company.

Stakeholder Impact

• Shareholders will receive distributions from the liquidation of the company.
• Employees of the Avenova business may be offered employment by PRN.
• Customers of Avenova will continue to have access to the product through PRN.
• Creditors will be paid as part of the liquidation process.

Next Steps

• NovaBay will file a proxy statement with the SEC to seek stockholder approval for the asset sale and dissolution.
• The company will hold a special meeting of stockholders to vote on the transaction.
• If approved, the company will proceed with the sale of Avenova assets and the liquidation process.
• The company will distribute net proceeds to stockholders after satisfying liabilities.

Key Dates

Keywords

Avenova, asset sale, liquidation, dissolution, eyecare, PRN, stockholders, net working capital, escrow, wind down